Prostate specific antigen kinetics following robotic stereotactic body radiotherapy for localized prostate cancer

References

• American Society for Radiation Oncology (ASTRO) Model Policy on Steretoactic Body Radiotherapy 2013. Available fromml: https://www.astro.org/uploadedFiles/Main_Site/Practice_Management/Reimbursement/2013HPcoding%20guidelines_SBRT_Final.pdf. Cited on 17th April, 2013.
   Google Scholar
• Dasu A, Toma-Dasu I. Prostate alpha/beta revisited – an analysis of clinical results from 14 168 patients. Acta Oncol 2012;51:963–74.
   PubMed Web of Science ®Google Scholar
• Miralbell R, Roberts SA, Zubizarreta E, Hendry JH. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: Alpha/beta = 1.4 (0.9–2.2) Gy. Int J Radiat Oncol Biol Phys 2011;82:e17–24.
   Google Scholar
• Proust-Lima C, Taylor JM, Secher S, Sandler H, Kestin L, Pickles T, et al. Confirmation of a low alpha/beta ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics. Int J Radiat Oncol Biol Phys 2010;79:195–201.
   PubMed Web of Science ®Google Scholar
• Chen LN, Suy S, Uhm S, Oermann EK, Ju AW, Chen V, et al. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: The Georgetown University experience. Radiat Oncol 2013;8:58.
   PubMed Web of Science ®Google Scholar
• Freeman DE, King CR. Stereotactic body radiotherapy for low-risk prostate cancer: Five-year outcomes. Radiat Oncol 2011;6:3.
   PubMed Web of Science ®Google Scholar
• Katz AJ, Santoro M, Diblasio F, Ashley R. Stereotactic body radiotherapy for localized prostate cancer: Disease control and quality of life at 6 years. Radiat Oncol 2013;8:118.
   PubMed Web of Science ®Google Scholar
• King CR, Brooks JD, Gill H, Presti JC, Jr. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys 2011;82:877–82.
   PubMed Web of Science ®Google Scholar
• McBride SM, Wong DS, Dombrowski JJ, Harkins B, Tapella P, Hanscom HN, et al. Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: Preliminary results of a multi-institutional phase 1 feasibility trial. Cancer 2011;118:3681–90.
   PubMed Web of Science ®Google Scholar
• Slomski A. USPSTF finds little evidence to support advising PSA screening in any man. JAMA 2011;306:2549–51.
   PubMed Web of Science ®Google Scholar
• Scherger JE. PSA screening: The USPSTF got it wrong. J Fam Pract 2013;62:616, 8.
   PubMed Web of Science ®Google Scholar
• Lefevre M. PSA screening: The USPSTF got it right. J Fam Pract 2013;62:617, 9.
   PubMed Web of Science ®Google Scholar
• Cheung R, Tucker SL, Kuban DA. First-year PSA kinetics and minima after prostate cancer radiotherapy are predictive of overall survival. Int J Radiat Oncol Biol Phys 2006;66: 20–4.
   PubMed Web of Science ®Google Scholar
• Ray ME, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, et al. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: A multi-institutional analysis. Int J Radiat Oncol Biol Phys 2006;64:1140–50.
   PubMed Web of Science ®Google Scholar
• Zietman AL, Tibbs MK, Dallow KC, Smith CT, Althausen AF, Zlotecki RA, et al. Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate. Radiother Oncol 1996;40:159–62.
   PubMed Web of Science ®Google Scholar
• Anwar M, Weinberg V, Chang AJ, Hsu IC, Roach M, 3rd, Gottschalk A. Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: Comparison of PSA slope and nadir. Radiat Oncol 2014;9:42.
   PubMedGoogle Scholar
• Hanlon AL, Moore DF, Hanks GE. Modeling postradiation prostate specific antigen level kinetics: Predictors of rising postnadir slope suggest cure in men who remain biochemically free of prostate carcinoma. Cancer 1998;83:130–4.
   PubMed Web of Science ®Google Scholar
• Semjonow A, Schmid HP. The rise and fall of PSA: Clinical implications of prostate specific antigen kinetics. Urol Res 2002;30:85–8.
   PubMedGoogle Scholar
• Denham JW, Lamb DS, Joseph D, Matthews J, Atkinson C, Spry NA, et al. PSA response signatures – a powerful new prognostic indicator after radiation for prostate cancer? Radiother Oncol 2009;90:382–8.
   PubMed Web of Science ®Google Scholar
• Vollmer RT, Montana GS. The dynamics of prostate-specific antigen after definitive radiation therapy for prostate cancer. Clin Cancer Res 1999;5:4119–25.
   PubMed Web of Science ®Google Scholar
• Vollmer RT. Dissecting the dynamics of serum prostate-specific antigen. Am J Clin Pathol 2010;133:187–93.
   PubMed Web of Science ®Google Scholar
• Vollmer RT, Humphrey PA. Tumor volume in prostate cancer and serum prostate-specific antigen. Analysis from a kinetic viewpoint. Am J Clin Pathol 2003;119:80–9.
   PubMed Web of Science ®Google Scholar
• Swanson KR, True LD, Lin DW, Buhler KR, Vessella R, Murray JD. A quantitative model for the dynamics of serum prostate-specific antigen as a marker for cancerous growth: An explanation for a medical anomaly. Am J Clin Pathol 2001;158:2195–9.
   Web of Science ®Google Scholar
• Ritter MA, Messing EM, Shanahan TG, Potts S, Chappell RJ, Kinsella TJ. Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. J Clin Oncol 1992;10:1208–17.
   PubMed Web of Science ®Google Scholar
• Zagars GK, Pollack A. The fall and rise of prostate-specific antigen. Kinetics of serum prostate-specific antigen levels after radiation therapy for prostate cancer. Cancer 1993; 72:832–42.
   PubMed Web of Science ®Google Scholar
• Kaplan ID, Cox RS, Bagshaw MA. A model of prostatic carcinoma tumor kinetics based on prostate specific antigen levels after radiation therapy. Cancer 1991;68:400–5.
   PubMed Web of Science ®Google Scholar
• Cavanaugh SX, Kupelian PA, Fuller CD, Reddy C, Bradshaw P, Pollock BH, et al. Early prostate-specific antigen (PSA) kinetics following prostate carcinoma radiotherapy: Prognostic value of a time-and-PSA threshold model. Cancer 2004;101:96–105.
   PubMed Web of Science ®Google Scholar
• Vu CC, Haas JA, Katz AE, Witten MR. Prostate-specific antigen bounce following stereotactic body radiation therapy for prostate cancer. Front Oncol 2014;4:8.
   PubMedGoogle Scholar
• Rosser CJ, Kamat AM, Wang X, Do KA, Sanchez-Ortiz RF, Kuban DA, et al. Is patient age a factor in the occurrence of prostate-specific antigen bounce phenomenon after external beam radiotherapy for prostate cancer? Urology 2005;66: 327–31.
   PubMed Web of Science ®Google Scholar
• Rosser CJ, Kuban DA, Levy LB, Chichakli R, Pollack A, Lee AK, et al. Prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer. J Urol 2002;168:2001–5.
   PubMed Web of Science ®Google Scholar
• Oesterling JE, Chan DW, Epstein JI, Kimball AW, Jr., Bruzek DJ, Rock RC, et al. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol 1988;139:766–72.
   PubMed Web of Science ®Google Scholar